GPC Biotech Announces Presentation of New Pre-Clinical Data on RGB-286638 Multi-Targeted Kinase Inhibitor at the American Society of Hematology Annual Meeting

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Martinsried/Munich (Germany) and Princeton, N.J., December 8, 2008 -
GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today
reported that new pre-clinical data on RGB-286638, the Company's
multi-targeted protein kinase inhibitor, were presented at the 50th
American Society of Hematology (ASH) Annual Meeting in San Francisco,
California in a poster entitled, "RGB-286638, a Novel Multi-Targeted
Small Molecule Inhibitor, Induces Multiple Myeloma (MM) Cell Death
through Abrogation of CDK-Dependent and Independent Survival
Mechanisms" (Poster Board II-853). The data presented demonstrate
that, in a mouse tumor model, RGB-286638 inhibits the growth of
multiple myeloma tumors and prolongs survival. Additionally,
RGB-286638 has been shown to trigger apoptosis (programmed cell
death) in multiple myeloma cells, including those cells that are
resistant to drugs commonly used to treat this form of cancer. The
data were presented by researchers at the Dana-Farber Cancer
Institute and the Massachusetts General Hospital Cancer Center (MGH),
Boston, Massachusetts.

"The data presented today suggest the potential role of RGB-286638 in
the treatment of multiple myeloma," said Martine George, M.D., Senior
Vice President, Drug Development and Chief Medical Officer of GPC
Biotech. "We are working with the MGH/Dana-Farber team to plan a
Phase 1 study in hematological tumors, including multiple myeloma,
which we expect to start in 2009. The first-in-humans study with
this compound, a Phase 1 trial evaluating RGB-286638 in solid tumors,
is expected to start in the near future."

About RGB-286638
RGB-286638 is a multi-targeted protein kinase inhibitor entering
Phase 1 clinical testing. The RGB-286638 compound has been shown in
cancer cells to lead to the inhibition of cell cycle progression, the
process that controls cell division and ensures the accurate
duplication of genetic material, by targeting all relevant
cyclin-dependent kinases, which are proteins involved in regulating
the cell cycle. RGB-286638 has also been shown to induce apoptosis
and to inhibit other major protein kinases that are important for the
proliferation of cancer cells. In a range of pre-clinical models of
solid and hematological tumors, RGB-286638 treatment results in tumor
regression and increased survival.

About GPC Biotech
GPC Biotech AG is a publicly traded biopharmaceutical company focused
on anticancer drugs. GPC Biotech's lead product candidate is
satraplatin, an oral platinum compound. The Company has various
anti-cancer programs in research and development that leverage its
expertise in kinase inhibitors. GPC Biotech AG is headquartered in
Martinsried/Munich (Germany) and has a wholly owned U.S. subsidiary
in Princeton, New Jersey. For additional information, please visit
GPC Biotech's Web site at www.gpc-biotech.com.

This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of GPC
Biotech. Such statements are based on current expectations and are
subject to risks and uncertainties, many of which are beyond our
control, that could cause future results, performance or achievements
to differ significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Actual
results could differ materially depending on a number of factors, and
we caution investors not to place undue reliance on the
forward-looking statements contained in this press release. There can
be no guarantee that RGB-286638 will be successfully developed. We
direct you to GPC Biotech's Annual Report on Form 20-F for the fiscal
year ended December 31, 2007 and other reports filed with the U.S.
Securities and Exchange Commission for additional details on the
important factors that may affect the future results, performance and
achievements of GPC Biotech. Forward-looking statements speak only as
of the date on which they are made and GPC Biotech undertakes no
obligation to update these forward-looking statements, even if new
information becomes available in the future.

For further information, please contact:

GPC Biotech AG
Additional media contacts for Europe:
Investor Relations MC
Services AG
& Corporate Communications Phone: +49
(0) 89 210 228 0
Phone: +49 (0)89 8565-2693
ir@gpc-biotech.com Raimund
Gabriel
raimund.gabriel@mc-services.eu

In the U.S.: Laurie Doyle Hilda
Juhasz
Director, Investor Relations
hilda.juhasz@mc-services.eu
& Corporate Communications
Phone: +1 609-524-5884 Additional
investor contact for Europe:
usinvestors@gpc-biotech.com Trout
International LLC

Lauren Rigg, Vice President
Phone: +44 207 936 9325
lrigg@troutgroup.com

--- End of Message ---

GPC Biotech AG
Fraunhoferstr. 20 Martinsried Germany

WKN: 585150;
ISIN: DE0005851505; Index: CDAX, MIDCAP, Prime All Share, TecDAX,
HDAX, TECH All Share;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Börse Berlin,
Freiverkehr in Bayerische Börse München, Freiverkehr in Börse
Düsseldorf,
Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische
Wertpapierbörse zu Hamburg,
Geregelter Markt in Frankfurter Wertpapierbörse;
Copyright © Hugin AS 2008. All rights reserved.